Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126372122 | 12637212 | 2 | F | 20160613 | 20160726 | 20160809 | 20160809 | EXP | US-TEVA-680753USA | TEVA | 36.00 | YR | M | Y | 0.00000 | 20160809 | OT | US | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126372122 | 12637212 | 1 | PS | FLUOROURACIL. | FLUOROURACIL | 1 | Unknown | U | 40333 | ||||||||||
| 126372122 | 12637212 | 2 | SS | OXALIPLATIN INJECTION | OXALIPLATIN | 1 | Unknown | U | 22160 | ||||||||||
| 126372122 | 12637212 | 3 | SS | LEUCOVORIN CALCIUM. | LEUCOVORIN CALCIUM | 1 | Unknown | U | 71198 | ||||||||||
| 126372122 | 12637212 | 4 | C | Cyclizine | CYCLIZINE | 1 | Unknown | 0 | |||||||||||
| 126372122 | 12637212 | 5 | C | MOTILIUM | DOMPERIDONE | 1 | Unknown | 0 | |||||||||||
| 126372122 | 12637212 | 6 | C | Clexane | ENOXAPARIN SODIUM | 1 | Unknown | 0 | |||||||||||
| 126372122 | 12637212 | 7 | C | Pantoprazole | PANTOPRAZOLE SODIUM | 1 | Unknown | 0 | |||||||||||
| 126372122 | 12637212 | 8 | C | CREON | PANCRELIPASE AMYLASEPANCRELIPASE LIPASEPANCRELIPASE PROTEASE | 1 | Unknown | 0 | |||||||||||
| 126372122 | 12637212 | 9 | C | LYRICA | PREGABALIN | 1 | Unknown | 0 | |||||||||||
| 126372122 | 12637212 | 10 | C | ARCOXIA | ETORICOXIB | 1 | Unknown | 0 | |||||||||||
| 126372122 | 12637212 | 11 | C | FENTANYL. | FENTANYL | 1 | Unknown | 0 | |||||||||||
| 126372122 | 12637212 | 12 | C | INCB018424 (Ruxolitinib + Capecitabine) | 2 | Oral | 4000 MILLIGRAM DAILY; | 0 | 2000 | MG | TABLET | BID |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 126372122 | 12637212 | 1 | Pancreatic carcinoma |
| 126372122 | 12637212 | 2 | Pancreatic carcinoma |
| 126372122 | 12637212 | 3 | Pancreatic carcinoma |
| 126372122 | 12637212 | 12 | Pancreatic carcinoma |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 126372122 | 12637212 | OT |
| 126372122 | 12637212 | HO |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 126372122 | 12637212 | Diarrhoea | |
| 126372122 | 12637212 | Nausea | |
| 126372122 | 12637212 | Obstruction gastric | |
| 126372122 | 12637212 | Vomiting |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 126372122 | 12637212 | 12 | 20150703 | 20160613 | 0 |